MWMeifang Wu

Meifang Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meifang Wu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Liming Lin

    Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, Fujian, China.

    9 shared publications
  • Meiyan Song

    Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, Fujian, China

    6 shared publications
  • Ying Wu

    Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, Fujian, China

    6 shared publications
  • Kaizu Xu

    Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, Fujian, China

    5 shared publications
  • Wen Chen

    Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, Fujian, China

    5 shared publications
  • Aiping Wu

    Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, Fujian, China

    2 shared publications

Latest Publications

  • Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review

    by Ying Wu, Meiyan Song, Xiaomin Chen, Wen Chen, Meifang Wu, Liming Lin

    Purpose of Review The global obesity epidemic has precipitated a surge in obesity-related heart failure with preserved ejection fraction (HFpEF), a distinct clinical phenotype characterized by exacerbated symptom burden, systemic inflammation, and impaired quality of life compared to non-obese HFpEF. While lifestyle modifications remain foundational, suboptimal adherence limits their efficacy. Bariatric surgery leads to the most dramatic and sustained weight loss but lacks a randomized trial for HFpEF-specific outcomes. Recent Findings Recent landmark trials (STEP-HFpEF, STEP-HFpEF DM, SUMMIT) demonstrate that incretin-based therapies—glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists—significantly ameliorate heart failure symptoms, attenuate heart failure worsening, and induce weight loss in obese HFpEF patients, irrespective of diabetes status. However, long-term cardiovascular mortality benefits and safety profiles require further validation. Sodium-glucose cotransporter-2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists MRAs exhibit prognostic benefits in HFpEF, with post hoc analyses suggesting enhanced efficacy in higher BMI subgroups. Conversely, angiotensin receptor-neprilysin inhibitors and the controlled metabolic accelerator HU6 lack randomized trials to support routine use. Summary A combination of incretin-based therapies, SGLT2 inhibitors, and non-steroidal MRAs may represent the optimal evidence-based strategy for obesity-related HFpEF at present. Future research should prioritize standardized definitions of obesity, BMI thresholds, weight loss targets, optimal combination strategies, and long-term outcome assessments.


  • miR-132 Inhibition Improves Cardiac Remodeling and Function in a Two-Hit Mouse Model of Heart Failure With a Preserved Ejection Fraction

    by Ying Wu, Meiyan Song, Wen Chen, Fengjin Liang, Kaizu Xu, Liming Lin, Meifang Wu

    To investigate the impact of antimiR-132, a miR-132 antisense inhibitor, on cardiac remodeling and function in a two-hit mouse model of heart failure with preserved ejection fraction (HFpEF), as well as its underlying mechanism. Male C57BL/6 mice were fed N(omega)-nitro- l -arginine methyl ester plus a high-fat diet to establish an HFpEF model and then intraperitoneally injected with antimiR-132 or normal saline. Cardiac fibroblasts treated with transforming growth factor β1 (TGF-β1) were cultured in the presence of antimiR-132 or vehicle to examine collagen synthesis and potential mechanisms. Compared with control mice, HFpEF mice showed significant increases in blood pressure, triglycerides, cholesterol, body weight, myocardial hypertrophy, and fibrosis. They also had elevated E/E′ ratios and plasma NT-proBNP levels. antimiR-132 did not significantly affect blood pressure or metabolic parameters in HFpEF mice; however, it notably ameliorated myocardial hypertrophy and fibrosis, while concurrently reducing E/E′ ratios and plasma NT-proBNP levels. Mechanistically, the cardioprotective effects of antimiR-132 were accompanied by inhibition of the upregulated expression of miR-132 and P-Smad3 protein in the myocardium, as well as reduction in TGF-β1–induced collagen synthesis and Smad3 phosphorylation in cardiac fibroblasts. Taken together, miR-132 inhibition ameliorated myocardial remodeling and diastolic dysfunction in HFpEF mice through downregulation of the miR-132/Smad3 pathway.


  • Open Access

    Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway

    by Aiping Wu, Ying Wu, Meiyan Song, Wen Chen, Kaizu Xu, Meifang Wu, Liming Lin

    To investigate the impact of liraglutide (LIR) on experimental hypercholesterolemia-associated atherosclerosis and endothelial-monocyte adhesion, as well as elucidate the involvement of lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1)/NF-κB signaling pathway in this process. High-fat diet-fed ApoE−/− mice were treated with LIR (300 mg/kg, subcutaneous injection, twice a week) or normal saline for 6 weeks. Normal diet-fed ApoE−/− and C57BL/6 mice were served as control. In parallel, thoracic aorta endothelial cells (TAECs) were exposed to ox-LDL (50 mg/L) in the presence or absence of LIR. The thoracic aorta histology and vasodilatory function, TAECs viability, monocyte adhesion to TAECs, as well as mRNA and protein levels of LOX-1, NF-κB p65, ICAM-1, and VCAM-1 in the thoracic aorta and TAECs were determined. LIR decreased plasma levels of triglyceride and total cholesterol, reduced aorta plaque size, improved endothelial-dependent relaxation, and inhibited the mRNA and protein expression levels of LOX-1, phosphorylated NF-κB p65, ICAM-1, and VCAM-1. Mechanistically, LIR or selective IκB kinase (IKK) inhibitor IKK-16 enhanced cell viability of TAECs, mitigated monocyte adhesion to TAECs, and reduced ICAM-1 and VCAM-1 mRNA and protein expression. Liraglutide improved vasodilation function and alleviated atherosclerosis by inhibiting endothelial-monocyte adhesion via downregulation of the LOX-1/NF-κB pathway.


  • Open Access

    Vericiguat Improves Cardiac Remodelling and Function in Rats with Doxorubicin-Induced Cardiomyopathy

    by Wen Chen, Ying Wu, Wei Li, Meiyan Song, Kaizu Xu, Meifang Wu, Liming Lin

    Purpose: Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in patients with doxorubicin (DOX)-induced cardiomyopathy (DIC). In this study, we investigated the effects of vericiguat on cardiac structure and function in rats with DIC as well as their potential mechanisms of action. Methods: DIC rats were established by intraperitoneal injection of DOX (1 mg/kg) twice a week for 6 weeks, followed by intragastric administration of vericiguat 1 mg/kg/day or an equal volume of normal saline for 8 weeks. Cardiac histology and function, circulating levels of amino-terminal pro-B-type natriuretic peptide (NT-proBNP), nitric oxide (NO), and oxidative indices, as well as myocardial cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signalling, oxidative and apoptosis-associated protein were measured. Results: Compared with the control group, rats treated with DOX exhibited significantly increased heart size, reduced systolic function and elevated plasma levels of NT-proBNP. Histological findings revealed myocardial cell atrophy, fibrosis and apoptosis. Vericiguat treatment effectively reversed DOX-induced cardiac remodelling and improved systolic function. Mechanistically, Vericiguat attenuated the inhibitory effects of DOX on the myocardial cGMP-PKG axis and nuclear factor erythroid 2-related factor 2 (Nrf2) protein, thereby alleviating oxidative stress and apoptosis. Conclusions: Vericiguat improved cardiac remodelling and contractile function in rats with DIC through upregulation of cGMP-PKG signalling and inhibition of oxidative stress and myocardial apoptosis.


  • Open Access

    Advances in Device-Based Treatment of Heart Failure with Preserved Ejection Fraction: Evidence from Clinical Trials

    by Ying Wu, Meiyan Song, Meifang Wu, Liming Lin

    Heart failure with preserved ejection fraction (HFpEF) is a group of clinical syndromes that exhibit a remarkably heterogeneous phenotype, characterized by symptoms and signs of heart failure, left ventricular diastolic dysfunction, elevated levels of natriuretic peptides, and an ejection fraction greater than or equal to 50%. With the aging of the population and the escalating prevalence of hypertension, obesity, and diabetes, the incidence of HFpEF is progressively rising. Drug therapy options for HFpEF are currently limited, and the associated high risk of cardiovascular mortality and heart failure rehospitalization significantly impact patients’ quality of life and longevity while imposing a substantial economic burden on society. Recent research indicates that certain device-based therapies may serve as valuable adjuncts to drug therapy in patients with specific phenotypes of HFpEF, effectively improving symptoms and quality of life while reducing the risk of readmission for heart failure. These include inter-atrial shunt and greater splanchnic nerve ablation to reduce left ventricular filling pressure, implantable heart failure monitor to guide diuresis, left atrial pacing to correct interatrial dyssynchrony, cardiac contractility modulation to enhance cardiac calcium handling, as well as renal denervation, baroreflex activation therapy, and vagus nerve stimulation to restore the autonomic imbalance. In this review, we provide a comprehensive overview of the mechanisms and clinical evidence pertaining to these devices, with the aim of enhancing therapeutic strategies for HFpEF.


  • Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials

    by Wu Meifang, Wu Ying, Chen Wen, Xu Kaizu, Song Meiyan, Lin Liming

    The prevalence of heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of the total heart failure population, and with the aging of the population and the increasing prevalence of hypertension, obesity, and type 2 diabetes (T2DM), the incidence of HFpEF continues to rise and has become the most common subtype of heart failure. Compared with heart failure with reduced ejection fraction, HFpEF has a more complex pathophysiology and is more often associated with hypertension, T2DM, obesity, atrial fibrillation, renal insufficiency, pulmonary hypertension, obstructive sleep apnea, and other comorbidities. HFpEF has generally been considered a syndrome with high phenotypic heterogeneity, and no effective treatments have been shown to reduce mortality to date. Diuretics and comorbidity management are traditional treatments for HFpEF; however, they are mostly empirical due to a lack of clinical evidence in the setting of HFpEF. With the EMPEROR-Preserved and DELIVER results, sodium-glucose cotransporter 2 inhibitors become the first evidence-based therapies to reduce rehospitalization for heart failure. Subgroup analyses of the PARAGON-HF, TOPCAT, and CHARM-Preserved trials suggest that angiotensin receptor-neprilysin inhibitors, spironolactone, and angiotensin II receptor blockers may be beneficial in patients at the lower end of the ejection fraction spectrum. Other potential pharmacotherapies represented by non-steroidal mineralocorticoid receptor antagonists finerenone and antifibrotic agent pirfenidone also hold promise for the treatment of HFpEF. This article intends to review the clinical evidence on current pharmacotherapies of HFpEF, as well as the comorbidities management of atrial fibrillation, hypertension, T2DM, obesity, pulmonary hypertension, renal insufficiency, obstructive sleep apnea, and iron deficiency, to optimize the clinical management of HFpEF.


  • Open Access

    1,25-dihydroxyvitamin D3 ameliorates high glucose-mediated proliferation, migration, and MCP-1 secretion of vascular smooth muscle cells by inhibiting MAPK phosphorylation

    by Xu Kaizu, Wu Ying, Wu Mei-Fang, Lin Li-Ming

    Objectives: To explore the impacts of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on the proliferation, migration, and monocyte chemoattractant protein-1 (MCP-1) secretion of vascular smooth muscle cells (VSMCs) in a high glucose environment and its possible mechanism. Methods: We extracted VSMCs from the thoracic aorta of a male Sprague–Dawley rats before culturing them in a 25-mM glucose-containing medium in the presence or absence of 1,25(OH)2D3 (10−9 –10−7 M). Cell proliferation was determined by bromodeoxyuridine incorporation assays. Subsequently, cell migratory capacity was examined by performing a transwell assay. An enzyme-linked immunosorbent assay was conducted to assess MCP-1 levels. Protein levels of matrix metalloproteinase-9 (MMP-9), mitogen-activated protein kinases (MAPKs), cyclin D1, and phosphorylated MAPKs were determined by immunoblotting. Results: 1,25(OH)2D3 significantly suppressed the proliferation, migration, and MCP-1 secretion of VSMCs mediated by high glucose in a dose-dependent manner, diminished the enhanced protein expression of MMP-9 and cyclin D1, and attenuated MAPK phosphorylation. The p38 inhibitor SB203580 and ERK1/2 inhibitor PD98059 suppressed high glucose-mediated upregulation of MMP-9 and cyclin D1 protein expression and MCP-1 secretion, respectively. Conclusions: 1,25(OH)2D3 ameliorates high glucose-mediated proliferation, migration, and MCP-1 secretion of VSMCs by inhibiting MAPK phosphorylation, implying a potential therapeutic approach using 1,25(OH)2D3 for diabetic macrovascular complications.

  • Open Access

    Advances in miR-132-Based Biomarker and Therapeutic Potential in the Cardiovascular System

    by Kaizu Xu, Chungui Chen, Ying Wu, Meifang Wu, Liming Lin

    Atherosclerotic cardiovascular disease and subsequent heart failure threaten global health and impose a huge economic burden on society. MicroRNA-132 (miR-132), a regulatory RNA ubiquitously expressed in the cardiovascular system, is up-or down-regulated in the plasma under various cardiac conditions and may serve as a potential diagnostic or prognostic biomarker. More importantly, miR-132 in the myocardium has been demonstrated to be a master regulator in many pathological processes of ischemic or nonischemic heart failure in the past decade, such as myocardial hypertrophy, fibrosis, apoptosis, angiogenesis, calcium handling, neuroendocrine activation, and oxidative stress, through downregulating target mRNA expression. Preclinical and clinical phase 1b studies have suggested antisense oligonucleotide targeting miR-132 may be a potential therapeutic approach for ischemic or nonischemic heart failure in the future. This review aims to summarize recent advances in the physiological and pathological functions of miR-132 and its possible diagnostic and therapeutic potential in cardiovascular disease.